Results 31 to 40 of about 7,079 (166)
Safety and Efficacy of Vigabatrin for the Treatment of Infantile Spasms
Journal of Central Nervous System Disease, 2011 In 2009, vigabatrin became the first FDA approved medication for the treatment of infantile spasms in the United States. There are few well-designed prospective studies comparing the drug to placebo or other modalities used in the treatment of infantile ...
Michele A. Faulkner, Justin A. Tolman
doaj +1 more source
Vigabatrin dosing during haemodialysis [PDF]
, 1996 The antiepileptic drug vigabatrin has shown efficacy in the treatment of patients with refractory epilepsy. Unlike many other antiepileptics it is not bound to plasma protein and mainly eliminated by the kidney.
Wad, Nils +3 more
core +1 more source
Neurobiology of Disease, 2004 Vigabatrin (VGB) has been widely used in patients affected by drug-resistant epilepsy and West syndrome. Following reports of visual field loss associated with vigabatrin therapy, some authors have investigated retinal electrophysiologic variables to ...
Pasquale Parisi +3 more
doaj +1 more source
Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine
, 2003 In the last decade, nine new antiepileptic drugs have reached the global marketplace. These new agents can be categorised according to their principal mechanisms of action.
Sills, Graeme J.
core +6 more sources
Towards a Synthesis of Vigabatrin Using Glycal Chemistry
Molecules, 2005 Application of the Ferrier rearrangement led to a novel carbohydrate based synthetic route to 4-aminohexenoic acid viz. (R) and (S)-vigabatrin. The potential of D- glucose or D-galactose as the chiral starting materials for the synthesis of (R) and (S ...
I. Aidhen, J. Aidhen, S. Boga
doaj +1 more source
The impact of medication shortages on paediatric care: A retrospective impact analysis
British Journal of Clinical Pharmacology, EarlyView.Aims Medication shortages are a growing global concern, with potentially greater consequences in paediatric patients because of the limited availability of safe, evidence‐based and appropriately formulated medication. This study aimed to evaluate the impact of medication shortages on paediatric patients by assessing the suitability and safety of ...
Maaike Johanna Rutten ‐ van Kranenburg +6 more
wiley +1 more source
The pharmacokinetics and neuropharmacological action of the new antiepileptic drugs vigabatrin and levetiracetam. [PDF]
, 2007 Epilepsy affects approximately 1% of the world population and is the most serious neurological conditions. In the UK, 30-35,000 new cases of epilepsy are diagnosed each year, resulting in a prevalence of 300,000 nationwide.
Tong, X.
core
, 2018 Vigabatrin is a second-generation antiepileptic drug characterized by a few antiepileptic indications, with a very good interaction profile in polytherapy.
Andrea E. Cavanna
core +1 more source
Microstructural injury to the optic nerve with vigabatrin treatment in West syndrome: A DTI study
Scientific ReportsTo evaluate optic nerve injury associated with vigabatrin treatment in children with West syndrome using diffusion tensor imaging. Thirty-five children with West syndrome (aged 9 days–22 months) were retrospectively analyzed and grouped as follows: (1 ...
Junjie Hu +7 more
doaj +1 more source
SUDEP and mortality in developmental and epileptic encephalopathies: A meta-analysis of randomized clinical trials and extension studies. [PDF]
EpilepsiaAbstract Objective Developmental and epileptic encephalopathies (DEEs) are associated with high premature mortality and increased risk of sudden unexpected death in epilepsy (SUDEP). However, epidemiological data remain limited, particularly for specific syndromes such as Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and infantile epileptic ...
Moro P +5 more
europepmc +2 more sources